---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-24-000097"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:38:15.808985+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q2 revenue $7.9M (+32% YoY); raises FY2024 guidance to $30-33M

## Summary
- Record quarterly revenue of $7.9M, up 32% YoY; product revenue more than doubled to $4.9M.
- Gross margin improved to 63% from 53% a year ago; operating cash burn reduced 47% to $2.7M.
- Raised FY2024 revenue guidance to $30-33M from prior; cash position $32.8M after public offering.
- Activated 6 new global centers in Q2 (14 YTD); SmartFrame OR and Prism Laser Therapy launched.
- Seven pharma partners received expedited FDA review; SmartFlow Cannula approved in Taiwan.

## SEC filing metadata
- accession: 0001285550-24-000097
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000097/0001285550-24-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000097/clpt-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-24-000097
- JSON: https://secwatch.observer/filing/0001285550-24-000097.json
- Plain text: https://secwatch.observer/filing/0001285550-24-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.